MCX, Max Healthcare, CarTrade, Dr Lal Among UBS' 8 Midcap Bets. The 45% Upside Comes With A Catch

Executive Brief • Key Highlights
Fast factual intelligence distilled for busy investors, executives, and answer bots:
- ✓UBS identified eight midcap stocks, including MCX, Max Healthcare, and CarTrade, for potential growth.
- ✓Analysts said the next phase of outperformance depends on individual stock selection rather than a broad rally.
- ✓They noted, "The scope for this broad-based outperformance to continue is now limited" due to rich market valuations.
Story at a Glance
- Category
- Indian Markets
- Reported By
- NDTV Profit
- Reading Speed
- 4 Minute(s)
- Market Focus
- India Economy
The sharp recovery in mid-cap and small-cap stocks may be entering a different phase, with UBS seeing less room for broad-based gains and turning its attention to companies with specific earnings triggers.
In a report titled India Mid Caps: Seeking Bottom-Up Outperformance, analysts Shaleen Kumar, Raksha Saraf and Angad Saluja said the rebound in Indian small and mid-cap stocks since their March lows had been much sharper than the recovery in large caps. But with valuations still rich and the macroeconomic environment uncertain, the brokerage believes the next leg of outperformance will depend more on individual stock selection.
UBS has identified eight stocks where company-specific developments and industry trends could support earnings growth. Shaily Engineering Plastics and CarTrade Tech lead the list, with the brokerage seeing 45% upside in both. Its other picks are Dr Lal PathLabs, Indian Hotels, Multi Commodity Exchange of India (MCX), APL Apollo Tubes, Shyam Metalics and Max Healthcare.
Unlock the Full Story with ArthNow Premium
To continue reading this complete financial story and in-depth market context, upgrade to ArthNow Premium. Enjoy unlimited access across Web and Mobile.
NDTV Profit
Read the full, original unfiltered story directly on the publisher's portal.
This brief is for information only and is not investment advice. ArthNow is not a SEBI-registered investment adviser and does not publish buy or sell recommendations. Original reporting is credited to the publisher named above. Read our editorial policy or report an error.